Advertisement
Advertisement
QUIT
Achieve Life Sciences, Inc.
5.56
USDSponsored
-0.31
-5.28%
Nov 20, 15:59 UTC -5
Closed
After-Market
5.64
+0.08
+1.44%
Achieve Life Sciences, Inc. (QUIT) Earnings
QUIT Earnings Reports
Positive Surprise Ratio
QUIT beat 1 of 2 last estimates.
50%
Next Report
Date of Next Report
Mar 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.21
Implied change from Q3 26 (Revenue/ EPS)
--
/+90.91%
Implied change from Q4 25 (Revenue/ EPS)
--
/-25.00%
Achieve Life Sciences, Inc. earnings per share and revenue
On Nov 10, 2026, QUIT reported earnings of -0.11 USD per share (EPS) for Q3 26, beating the estimate of -0.20 USD, resulting in a 46.13% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.21 USD, with revenue projected to reach -- USD, implying an increase of 90.91% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were Achieve Life Sciences, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Achieve Life Sciences, Inc. reported EPS of -$0.11, beating estimates by 46.13%, and revenue of $0.00, 0% as expectations.
How did the market react to Achieve Life Sciences, Inc.'s Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Achieve Life Sciences, Inc. expected to report next?
The next earning report is scheduled for Mar 22, 2027.
What are the forecasts for Achieve Life Sciences, Inc.'s next earnings report?
Based on --
analysts, Achieve Life Sciences, Inc. is expected to report EPS of -$0.21 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.